Delta-9-tetrahydrocannabiol (THC) and cannabidiol (CBD)
We have developed and manufactured Sativex. All requests for product information and adverse events reporting should be directed through the distributor in that country/region.
Sativex® is marketed in the UK by GW Pharmaceuticals If you are a medical professional and would like further information on Sativex® please contact us using the details below.
T +44 (0) 1223 2381 170
Side effects should be reported. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk
Almirall S.A. is GW’s partner in Europe and therefore any enquiries relating to Sativex® from medical professionals in Europe should be directed to Almirall using their website.
Sativex is approved and commercialized in the following countries in mainland Europe: Germany, Italy, Spain, Belgium, Luxembourg, Norway, Denmark, Sweden, Iceland, Portugal, Poland, Austria and Switzerland, while it is approved in France, Rep of Ireland, Finland, Czech Rep, Slovakia and The Netherlands but not yet available.
In all of these countries other than Switzerland the marketing authorization for Sativex is held by GW Pharma. The marketing authorization for Sativex in Switzerland is held by Almirall S.A.’s Swiss affiliate.
If you are a medical professional in Europe and would like further information on Sativex please contact Almirall using the following link:
Bayer Canada is GW’s partner in Canada and therefore any enquiries relating to Sativex® from medical professionals in Canada should be directed to Bayer. If you are a medical professional in Canada and would like further information on Sativex please contact Bayer Canada using the following information:
T (1) 800 265 7382
F (1) 866 232 0565
Chiesi Australia PTY LTD are the legally registered Sponsor for Sativex in Australia and New Zealand and are currently working with local health authorities to enable supply of Sativex in each country. For information on its availability in Australia and New Zealand, please contact Chiesi Australia:
P 22 Gillman Street, Suite 3, Hawthorn East, Victoria 3123, Australia
T +61 (0)3 9077 4486
Neopharm Ltd is GW’s partner in Israel and therefore any enquiries relating to Sativex® from medical professionals in Israel should be directed to Neopharm.
Neopharm’ s medical department contact is: Medical Affairs Department
T +972 03 9373753
For Latin America GW Pharmaceuticals has partnered with Beaufour Ipsen Pharmaceuticals.
In Brazil Sativex® has received marketing authorization under the brand name of Mevatyl® and is indicated as treatment for symptoms improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
Sativex® has also received marketing authorization in Colombia and Chile for the same indication.
Sativex is not currently approved for use in the United States of America.
Medical professionals in the USA wishing to obtain more information on Sativex® (nabiximols) should contact:
Medical professionals wishing to obtain more information on Sativex® in countries where it is awaiting approval should contact IDIS Limited who specialise in the supply of unlicensed medicines: